Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides
Charles A. Dinarello, Denver, CO (US); and Soohyun Kim, Greenwood Village, CO (US)
Assigned to The Regents of the University of Colorado, Denver, CO (US); and Konkuk University Industry Cooperation Foundation, Chungju (KR)
Filed by The Regents of the University of Colorado, Denver, CO (US); and Konkuk University Industry Cooperation Foundation, Chungju (KR)
Filed on Sep. 10, 2021, as Appl. No. 17/471,466.
Application 17/471,466 is a continuation of application No. 16/572,371, filed on Sep. 16, 2019, abandoned.
Application 16/572,371 is a continuation of application No. 15/921,469, filed on Mar. 14, 2018, granted, now 10,450,384, issued on Oct. 22, 2019.
Application 15/921,469 is a continuation of application No. 14/125,135, granted, now 9,938,353, issued on Apr. 10, 2018, previously published as PCT/US2012/043869, filed on Jun. 22, 2012.
Claims priority of provisional application 61/500,795, filed on Jun. 24, 2011.
Prior Publication US 2022/0204646 A1, Jun. 30, 2022
1. A method for at least one of ameliorating inflammation and inhibiting an immune response in a subject comprising, administering to the subject in need thereof an effective amount of an isolated fusion polypeptide comprising a first polypeptide comprising an alpha-1 antitrypsin (AAT) polypeptide or a carboxyterminal fragment thereof, wherein the AAT polypeptide or carboxyterminal fragment thereof comprises SEQ ID NO: 1, SEQ ID NO: 33, and a second polypeptide comprising an immunoglobulin Fc polypeptide, wherein the isolated fusion polypeptide is part of a pharmaceutical composition.